On 16 October 2019, Jiangsu Bioperfectus Technologies Company Ltd's ("JBTCL") Initial Public Offering and Listing was approved by the Listing Committee for Stocks on the Science and Technology Innovation Board.
JBTCL is one of the leading domestic enterprises in the field of molecular diagnosis, an important suppliers of nucleic acid detection products in the disease prevention and control products industry.
Llinks provided legal services for JBTCL, assisting the company during the entire IPO process.
